Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.

doi:10.1016/j.celrep.2023.112297

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.

Cell reports - 25 Apr 2023

Tiedt Ralph, King Frederick J, Stamm Christelle, Niederst Matthew J, Delach Scott, Zumstein-Mecker Sabine, Meltzer Jodi, Mulford Iain J, Labrot Emma, Engstler Barbara Schacher, Baltschukat Sabrina, Kerr Grainne, Golji Javad, Wyss Daniel, Schnell Christian, Ainscow Edward, Engelman Jeffrey A, Sellers William R, Barretina Jordi, Caponigro Giordano, Porta Diana Graus

Abstract excerpt

Anti-tumor efficacy of targeted therapies is variable across patients and cancer types. Even in patients with initial deep response, tumors are typically not eradicated and eventually relapse. To address these challenges, we present a systematic screen for targets that limit the anti-tumor efficacy of EGFR and ALK inhibitors in non-small cell lung cancer and BRAF/MEK inhibitors in colorectal cancer. Our approach...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clustered Regularly Interspaced Short Palindromic Repeats

Share to ErbB Receptors

Share to Mitogen-Activated Protein Kinase Kinases

Share to Neoplasm Recurrence, Local

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Receptor Protein-Tyrosine Kinases

Source

Open in PubMed

Identifiers

PMID: 36961816
DOI: 10.1016/j.celrep.2023.112297

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.PMID 36961816Read ↗

Identifying chemogenetic interactions from CRISPR knockout screens with drugZSemantic proximity Read ↗

A CRISPR-drug perturbational map for identifying compounds to combine with commonly used chemotherapeuticsSemantic proximity Read ↗

A CRISPR-drug perturbational map for identifying new compounds to combine with commonly used chemotherapeuticsSemantic proximity Read ↗

Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screeningSemantic proximity Read ↗

New strategies for targeting drug combinations to overcome mutation-driven drug resistance.Semantic proximity Read ↗

Systematic identification of combinatorial drivers and targets in cancer cell lines.Semantic proximity Read ↗

A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.Semantic proximity Read ↗

Patient-derived models of acquired resistance can identify effective drug combinations for cancer.Semantic proximity Read ↗

Combination therapy for HCC: from CRISPR screening to the design of clinical therapiesSemantic proximity Read ↗

Identifying chemogenetic interactions from CRISPR screens with drugZSemantic proximity Read ↗

CRISPR screening and cell line IC50 data reveal novel key genes for trametinib resistanceSemantic proximity Read ↗

Pharmacogenomic discovery of genetically targeted cancer therapies optimized against clinical outcomesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.